Last reviewed · How we verify

DE-108 — Competitive Intelligence Brief

DE-108 (DE-108) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ROCK inhibitor. Area: Ophthalmology.

phase 3 ROCK inhibitor ROCK (Rho-associated coiled-coil-containing protein kinase) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

DE-108 (DE-108) — Santen Pharmaceutical Co., Ltd.. DE-108 is a small molecule that inhibits Rho-associated protein kinase (ROCK) to reduce intraocular pressure by decreasing aqueous humor outflow resistance.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DE-108 TARGET DE-108 Santen Pharmaceutical Co., Ltd. phase 3 ROCK inhibitor ROCK (Rho-associated coiled-coil-containing protein kinase)
SHR8028 eye drops SHR8028 eye drops Jiangsu HengRui Medicine Co., Ltd. phase 3 ROCK inhibitor ROCK (Rho-associated coiled-coil-containing protein kinase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ROCK inhibitor class)

  1. Aldeyra Therapeutics, Inc. · 1 drug in this class
  2. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
  3. Santen Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DE-108 — Competitive Intelligence Brief. https://druglandscape.com/ci/de-108. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: